GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (NAS:TWST) » Definitions » Piotroski F-Score

TWST (Twist Bioscience) Piotroski F-Score : 3 (As of Oct. 29, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Twist Bioscience Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Twist Bioscience has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Twist Bioscience's Piotroski F-Score or its related term are showing as below:

TWST' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 3

During the past 8 years, the highest Piotroski F-Score of Twist Bioscience was 5. The lowest was 2. And the median was 4.


Twist Bioscience Piotroski F-Score Historical Data

The historical data trend for Twist Bioscience's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience Piotroski F-Score Chart

Twist Bioscience Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Piotroski F-Score
Get a 7-Day Free Trial 5.00 4.00 4.00 3.00 2.00

Twist Bioscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 3.00 2.00 3.00

Competitive Comparison of Twist Bioscience's Piotroski F-Score

For the Diagnostics & Research subindustry, Twist Bioscience's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Twist Bioscience's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Twist Bioscience's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Net Income was -46.243 + -43.008 + -45.492 + -85.571 = $-220.3 Mil.
Cash Flow from Operations was -20.704 + -22.973 + -19.423 + -6.378 = $-69.5 Mil.
Revenue was 66.946 + 71.498 + 75.302 + 81.464 = $295.2 Mil.
Gross Profit was 24.522 + 28.962 + 30.882 + 35.271 = $119.6 Mil.
Average Total Assets from the begining of this year (Jun23)
to the end of this year (Jun24) was
(810.332 + 776.403 + 732.815 + 702.846 + 638.118) / 5 = $732.1028 Mil.
Total Assets at the begining of this year (Jun23) was $810.3 Mil.
Long-Term Debt & Capital Lease Obligation was $72.6 Mil.
Total Current Assets was $361.8 Mil.
Total Current Liabilities was $73.8 Mil.
Net Income was -51.115 + -41.824 + -59.156 + -57.395 = $-209.5 Mil.

Revenue was 57.306 + 54.243 + 60.18 + 63.74 = $235.5 Mil.
Gross Profit was 25.72 + 24.801 + 18.511 + 21.895 = $90.9 Mil.
Average Total Assets from the begining of last year (Jun22)
to the end of last year (Jun23) was
(979.663 + 961.378 + 909.97 + 853.924 + 810.332) / 5 = $903.0534 Mil.
Total Assets at the begining of last year (Jun22) was $979.7 Mil.
Long-Term Debt & Capital Lease Obligation was $79.9 Mil.
Total Current Assets was $445.5 Mil.
Total Current Liabilities was $72.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Twist Bioscience's current Net Income (TTM) was -220.3. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Twist Bioscience's current Cash Flow from Operations (TTM) was -69.5. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun23)
=-220.314/810.332
=-0.27188115

ROA (Last Year)=Net Income/Total Assets (Jun22)
=-209.49/979.663
=-0.21383884

Twist Bioscience's return on assets of this year was -0.27188115. Twist Bioscience's return on assets of last year was -0.21383884. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Twist Bioscience's current Net Income (TTM) was -220.3. Twist Bioscience's current Cash Flow from Operations (TTM) was -69.5. ==> -69.5 > -220.3 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=72.625/732.1028
=0.09920055

Gearing (Last Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=79.9/903.0534
=0.0884776

Twist Bioscience's gearing of this year was 0.09920055. Twist Bioscience's gearing of last year was 0.0884776. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun24)=Total Current Assets/Total Current Liabilities
=361.831/73.757
=4.90571742

Current Ratio (Last Year: Jun23)=Total Current Assets/Total Current Liabilities
=445.537/72.822
=6.11816484

Twist Bioscience's current ratio of this year was 4.90571742. Twist Bioscience's current ratio of last year was 6.11816484. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Twist Bioscience's number of shares in issue this year was 58.145. Twist Bioscience's number of shares in issue last year was 57.041. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=119.637/295.21
=0.40526066

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=90.927/235.469
=0.38615274

Twist Bioscience's gross margin of this year was 0.40526066. Twist Bioscience's gross margin of last year was 0.38615274. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun23)
=295.21/810.332
=0.36430747

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun22)
=235.469/979.663
=0.24035714

Twist Bioscience's asset turnover of this year was 0.36430747. Twist Bioscience's asset turnover of last year was 0.24035714. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Twist Bioscience has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Twist Bioscience  (NAS:TWST) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Twist Bioscience Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Twist Bioscience's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Twist Bioscience Business Description

Traded in Other Exchanges
Address
681 Gateway Boulevard, South San Francisco, CA, USA, 94080
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
Executives
Dennis Cho officer: See Remarks C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Emily M. Leproust director, officer: President & CEO C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Paula Green officer: VP of Human Resources C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Patrick John Finn officer: VP of Sales and Marketing C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
William Banyai director, officer: Chief Operating Officer C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Robert Chess director
Melissa A. Starovasnik director C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jan Johannessen director 5555 NE MOORE CT., HILLSBORO OR 97124
James M Thorburn officer: Chief Financial Officer C/O ZILOG INC, 532 RACE STREET, SAN JOSE CA 95126
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Patrick Weiss officer: VP of Operations C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Keith Crandell director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Kevin Bruce Yankton officer: Chief Accounting Officer 1678 S. PIONEER ROAD, SALT LAKE CITY UT 84104
Mark Daniels officer: Chief Compliance Officer & GC C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158